315703-81-2
315703-81-2
Chemical Structure
GM-90257
- CAS No.: 315703-81-2
- Formula:C16H14N4OS2
- Molecular Weight:342.44
InChIKey: YYYAGFCFCHCRAN-UHFFFAOYSA-N
SMILES: CC(N=C1SC=CN12)=C2C3=CSC(NC4=CC=C(C=C4)OC)=N3
Biological Activity: GM-90257 is a microtubule acetylation inhibitor. GM-90257 binds directly to α-tubulin. GM-90257 prevents the recruitment of α-tubulin acetyltransferase 1 (αTAT1) to the K40 residue in α-tubulin. GM-90257 causes Apoptosis, downregulates BCl-2, and activates JNK and PARP. GM-90257 has anticancer activity against breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GM-90257 | 99.90% | GM-90257 is a microtubule acetylation inhibitor. GM-90257 binds directly to α-tubulin. GM-90257 prevents the recruitment of α-tubulin acetyltransferase 1 (αTAT1) to the K40 residue in α-tubulin. GM-90257 causes Apoptosis, downregulates BCl-2, and activates JNK and PARP. GM-90257 has anticancer activity against breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.80
HY-163470Luciferase activator-1 -
Similarity Score 0.68
HY-13307JK184 -
Similarity Score 0.59
HY-15888PTC-209 -
Similarity Score 0.58
HY-15888APTC-209 hydrobromide -
Similarity Score 0.56
HY-151115JNJ-1289 -
Similarity Score 0.55
HY-15961Antitumor agent-3 -
Similarity Score 0.54
HY-157913PKM2-IN-6 -
Similarity Score 0.53
HY-171955LXG6403 -
Similarity Score 0.52
HY-159006CYP1B1 ligand 3 -
Explore the MedChemAI to find more analogs
References
- [1]. Ahreum Kwon, et al. Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer. Biomedicines. 2020 Sep 9;8(9):338. [Content Brief]
- [2]. Ahn S, et al. Microtubule Acetylation-Specific Inhibitors Induce Cell Death and Mitotic Arrest via JNK/AP-1 Activation in Triple-Negative Breast Cancer Cells. Mol Cells. 2023 Jun 30;46(6):387-398. [Content Brief]
